Table 2.
Univariate and multivariate Cox proportional hazards models
| Progression-free survival, HR (95% CI); P value | Overall survival, HR (95% CI); P value | |||
|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |
| EGFR-activating mutation | ||||
| Age | 1.00 (0.98–1.02); 0.73 | 1.01 (0.98–1.03); 0.60 | 1.00 (0.98–1.02); 0.99 | 1.02 (0.99–1.04); 0.23 |
| Gender | 1.00 (0.63–1.58); 0.99 | 1.35 (0.84–2.19); 0.22 | 0.91 (0.55–1.50); 0.70 | 1.30 (0.77–2.22); 0.33 |
| Metastases | 2.06 (1.24–3.41); 0.005 | 2.07 (1.23–3.47); 0.006 | 1.96 (1.11–3.45); 0.02 | 2.03 (1.13–3.65); 0.02 |
| EGFR tissue genotype | 1.39 (1.00–1.93); 0.048 | 1.64 (1.16–2.33); 0.005 | 1.36 (0.94–1.95); 0.10 | 1.57 (1.07–2.30); 0.02 |
| First-line EGFR TKI therapy | 1.06 (0.89–1.26); 0.52 | 1.13 (0.95–1.36); 0.17 | 1.16 (0.96–1.42); 0.13 | 1.27 (1.04–1.56); 0.02 |
| Activating mutation lg10 | 1.24 (1.12–1.36); < 0.0001 | 1.26 (1.15–1.39); < 0.0001 | 1.29 (1.15–1.44); < 0.0001 | 1.32 (1.18–1.47); < 0.0001 |
| EGFR T790M | ||||
| Age | 1.00 (0.98–1.02); 0.73 | 1.00 (0.98–1.02); 0.92 | 1.00 (0.98–1.02); 0.99 | 1.01 (0.99–1.03); 0.46 |
| Gender | 1.00 (0.63–1.58); 0.99 | 1.13 (0.70–1.82); 0.63 | 0.91 (0.55–1.50); 0.70 | 1.03 (0.61–1.74); 0.92 |
| Metastases | 2.06 (1.24–3.41); 0.005 | 2.12 (1.27–3.56); 0.004 | 1.96 (1.11–3.45); 0.02 | 2.03 (1.14–3.63); 0.02 |
| EGFR tissue genotype | 1.39 (1.00–1.93); 0.048 | 1.56 (1.10–2.20); 0.01 | 1.36 (0.94–1.95); 0.10 | 1.54 (1.05–2.26); 0.03 |
| First-line EGFR TKI therapy | 1.06 (0.89–1.26); 0.52 | 1.06 (0.88–1.28); 0.54 | 1.16 (0.96–1.42); 0.13 | 1.20 (0.97–1.48); 0.09 |
| T790M lg10 | 1.19 (0.99–1.42); 0.06 | 1.19 (0.99–1.42); 0.05 | 1.25 (1.02–1.53); 0.03 | 1.25 (1.02–1.53); 0.03 |
| EGFR T790M/activating mutation | ||||
| Age | 1.00 (0.98–1.02); 0.73 | 1.01 (0.98–1.03); 0.62 | 1.00 (0.98–1.02); 0.99 | 1.02 (0.99–1.05); 0.24 |
| Gender | 1.00 (0.63–1.58); 0.99 | 1.21 (0.73–2.02); 0.46 | 0.91 (0.55–1.50); 0.70 | 1.23 (0.71–2.15); 0.47 |
| Metastases | 2.06 (1.24–3.41); 0.005 | 2.03 (1.32–3.64); 0.02 | 1.96 (1.11–3.45); 0.02 | 2.00 (1.04–3.83); 0.04 |
| EGFR tissue genotype | 1.39 (1.00–1.93); 0.048 | 1.93 (1.31–2.84); 0.001 | 1.36 (0.94–1.95); 0.10 | 1.87 (1.22–2.86); 0.004 |
| First-line EGFR TKI therapy | 1.06 (0.89–1.26); 0.52 | 1.24 (1.02–1.51); 0.03 | 1.16 (0.96–1.42); 0.13 | 1.33 (1.07–1.65); 0.01 |
| EGFR T790M/activating mutation | 0.73 (0.52–1.04); 0.08 | 0.72 (0.51–1.02); 0.07 | 0.83 (0.60–1.15); 0.26 | 0.83 (0.60–1.15); 0.25 |
Variables were coded as described in “Patients and Methods”
CI confidence interval, EGFR epidermal growth factor receptor, HR hazard ratio, TKI tyrosine kinase inhibitor